Stay updated with breaking news from Ar T. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A duo of cases from the Federal Circuit has added complexities to the drafting of patent applications for antibody inventions, explain Hailey Bureau of BSKB and Olayinka Oladele of the Thurgood Marshall School of Law.
Tyrosine kinase inhibitors and novel agents like bi-specific T-cell engager and antibody drug conjugates have diminished the need for chemotherapy in adults with acute lymphoblastic leukemia (ALL).
We hit the dregs of time-killing TV Christmas specials in this week's edition of Clint Walker's THROWBACK MACHINE!
Merck and Eisai's Lenvima failed a Keytruda combo trial in newly diagnosed lung cancer. Johnson & Johnson and Legend Biotech's CAR-T posted a long tail to disease progression. AstraZeneca and Samsung Biologics included AZ's COVID antibody in their contract manufacturing deal. And more.
Tisagenlecleucel failed to outperform standard of care treatment when given as a second-line treatment for certain patients with relapsed/refractory aggressive non-Hodgkin lymphomas in the BELINDA trial.